Plant Stanols and Gene Expression Profile
Primary Purpose
Hypercholesterolemia
Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
control margarine
plant stanol-enriched margarine
Sponsored by
About this trial
This is an interventional prevention trial for Hypercholesterolemia focused on measuring Plant stanols, Gene expression profile, Microbiota
Eligibility Criteria
Inclusion Criteria:
- Aged between 18-60 years
- BMI between 20-30kg/m2
- mean serum total cholesterol < 7.8mmol/L
Exclusion Criteria:
- unstable body weight
- active cardiovascular diseases
- gastrointestinal diseases
- use of cholesterol-lowering drugs
- use of lipid-lowering therapy
- abuse of drug or alcohol
- pregnant or breast-feeding women
- current smoker
Sites / Locations
- Maastricht University Medical Centre
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Plant stanol-enriched margarine
control margarine
Arm Description
Outcomes
Primary Outcome Measures
intestinal mucosal gene expression profiles
Secondary Outcome Measures
microbiota composition
lipoprotein profile
plasma glucose concentration
plasma plant stanol concentration
Full Information
NCT ID
NCT01574417
First Posted
March 20, 2012
Last Updated
October 24, 2012
Sponsor
Maastricht University Medical Center
Collaborators
Raisio Group
1. Study Identification
Unique Protocol Identification Number
NCT01574417
Brief Title
Plant Stanols and Gene Expression Profile
Official Title
The Effects of Plant Stanol Esters on Intestinal Mucosal Gene Expression Profiles and Microbiota Composition in Healthy Human Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
October 2012
Overall Recruitment Status
Completed
Study Start Date
March 2012 (undefined)
Primary Completion Date
October 2012 (Actual)
Study Completion Date
October 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maastricht University Medical Center
Collaborators
Raisio Group
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Plant sterols and stanols are dietary components that are naturally present in plants. Their biological function in plants is comparable with these of cholesterol in animals. They are structurally related to cholesterol, but are absorbed by enterocytes to a much lesser extent. It is generally accepted that they inhibit intestinal cholesterol absorption and consequently lower serum low-density lipoprotein (LDL) cholesterol concentrations up to 10% at daily intakes of 2.5 g. The exact underlying mechanism of the plant sterol/stanol mediated reduction in intestinal cholesterol absorption is still unknown. It has been suggested that they lower the activity of sterol uptake transporters like Niemann-Pick C1 like 1 protein (NPC1L1) in enterocytes, otherwise several studies indicated that these compounds could activate the liver X receptor (LXR) in enterocytes, thereby activating the ABC transporters involved in the intestinal cholesterol metabolism, whereas recently suggestions have been made that plant sterols and stanols activate transintestinal cholesterol excretion (TICE). This is the direct cholesterol secretion from the blood into the intestinal lumen, in which the enterocytes play a central role. None of these assumptions have so far been evaluated in humans.
Objective: The major objective of the present study is to examine the acute effects of dietary plant stanol esters on the intestinal mucosal gene expression profiles in intestinal biopsies in healthy volunteers. The minor objective is to investigate whether semi-long-term use (3 weeks) of plant stanol esters have an effect on microbiota composition.
Detailed Description
lant sterols and stanols are dietary components that are naturally present in plants. Their biological function in plants is comparable with these of cholesterol in animals. They are structurally related to cholesterol, but are absorbed by enterocytes to a much lesser extent. It is generally accepted that they inhibit intestinal cholesterol absorption and consequently lower serum low-density lipoprotein (LDL) cholesterol concentrations up to 10% at daily intakes of 2.5 g. The exact underlying mechanism of the plant sterol/stanol mediated reduction in intestinal cholesterol absorption is still unknown. It has been suggested that they lower the activity of sterol uptake transporters like Niemann-Pick C1 like 1 protein (NPC1L1) in enterocytes, otherwise several studies indicated that these compounds could activate the liver X receptor (LXR) in enterocytes, thereby activating the ABC transporters involved in the intestinal cholesterol metabolism, whereas recently suggestions have been made that plant sterols and stanols activate transintestinal cholesterol excretion (TICE). This is the direct cholesterol secretion from the blood into the intestinal lumen, in which the enterocytes play a central role. None of these assumptions have so far been evaluated in humans.
Objective: The major objective of the present study is to examine the acute effects of dietary plant stanol esters on the intestinal mucosal gene expression profiles in intestinal biopsies in healthy volunteers. The minor objective is to investigate whether semi-long-term use (3 weeks) of plant stanol esters have an effect on microbiota composition.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypercholesterolemia
Keywords
Plant stanols, Gene expression profile, Microbiota
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Plant stanol-enriched margarine
Arm Type
Experimental
Arm Title
control margarine
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
control margarine
Intervention Description
Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the control margarine is consumed together with a high-fat milkshake.
Daily consumption of 20 gram of a control margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
plant stanol-enriched margarine
Intervention Description
Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake.
Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks.
Primary Outcome Measure Information:
Title
intestinal mucosal gene expression profiles
Time Frame
Measured at day 8 and day 64. Changes will be calculated between day 8 and day 64.
Secondary Outcome Measure Information:
Title
microbiota composition
Time Frame
measured after 3 weeks consumption of controle margarine and the plant stanol-enriched margarine. Changes will be calculated between these 2 interventions.
Title
lipoprotein profile
Time Frame
measured at baseline and after 3 weeks
Title
plasma glucose concentration
Time Frame
measured at day 8 and day 64, on 8 time points
Title
plasma plant stanol concentration
Time Frame
measured at baseline and after 3 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Aged between 18-60 years
BMI between 20-30kg/m2
mean serum total cholesterol < 7.8mmol/L
Exclusion Criteria:
unstable body weight
active cardiovascular diseases
gastrointestinal diseases
use of cholesterol-lowering drugs
use of lipid-lowering therapy
abuse of drug or alcohol
pregnant or breast-feeding women
current smoker
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jogchum Plat, Dr
Organizational Affiliation
Maastricht University Medical Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maastricht University Medical Centre
City
Maastricht
State/Province
Limburg
Country
Netherlands
12. IPD Sharing Statement
Learn more about this trial
Plant Stanols and Gene Expression Profile
We'll reach out to this number within 24 hrs